Mass. General Laws c.176B § 4PP

This is an unofficial version of a Massachusetts General Law. For more information on this topic, please see law about health insurance.

Updates

• Added by St.2021, c.29, § 24, effective July 1, 2021.
• Repealed by St.2021, c.20, § 25, effective July 1, 2022. 

(a)

For the purposes of this section, “long-term antibiotic therapy” and “Lyme disease” shall have the meaning ascribed to them in section 12DD of chapter 112.

(b)

A subscription certificate under an individual or group medical service agreement delivered, issued or renewed within the commonwealth shall provide coverage for long-term antibiotic therapy for a patient with Lyme disease when determined to be medically necessary and ordered by a licensed physician after making a thorough evaluation of the patient’s symptoms, diagnostic test results or response to treatment. An experimental drug shall be covered as a long-term antibiotic therapy if it is approved for an indication by the United States Food and Drug Administration; provided, however, that a drug, including an experimental drug, shall be covered for an off-label use in the treatment of Lyme disease if the drug has been approved by the United States Food and Drug Administration.

Last updated:	July 29, 2021